11/21
07:39 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
11/21
07:30 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/8
08:46 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
11/7
02:31 am
trvi
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
11/6
04:05 pm
trvi
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30
04:05 pm
trvi
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Medium
Report
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
10/22
08:32 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/21
07:30 am
trvi
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Medium
Report
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
10/15
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Low
Report
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
10/7
11:28 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
10/4
01:35 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Neutral
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
10/3
04:05 pm
trvi
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Neutral
Report
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
9/30
05:38 pm
trvi
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer [Yahoo! Finance]
9/30
05:30 pm
trvi
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
Medium
Report
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
9/26
07:30 am
trvi
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Low
Report
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
9/25
04:26 am
trvi
Chronic Refractory Cough Pipeline Landscape Report 2024 Featuring GSK and Trevi Therapeutics [Yahoo! Finance]
Medium
Report
Chronic Refractory Cough Pipeline Landscape Report 2024 Featuring GSK and Trevi Therapeutics [Yahoo! Finance]
9/10
05:58 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/9
09:01 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
9/4
04:05 pm
trvi
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
Medium
Report
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
8/30
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.00 price target on the stock.
8/30
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Raymond James. They set an "outperform" rating and a $9.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Raymond James. They set an "outperform" rating and a $9.00 price target on the stock.
8/28
07:30 am
trvi
Trevi Therapeutics to Participate in September Investor and Medical Conferences
Low
Report
Trevi Therapeutics to Participate in September Investor and Medical Conferences